Device Monitoring Fluid Build-Up in Adults With Heart Failure

Trial details

Who runs it

Heartfelt Technologies

Trial code

NCT07067658

Record updated

28 July 2026

Original description

This study will evaluate the Heartfelt device, a novel, passive monitoring system that detects early signs of fluid build-up in patients (oedema) with heart failure by measuring changes in foot and lower leg volume through capture of 3D images. The trial will assess whether this device, when added to standard NHS care, improves quality of life and reduces heart failure-related events compared to standard care alone.Read full original descriptionShow less

Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk

This study will evaluate the Heartfelt device, a novel, passive monitoring system that detects early signs of fluid build-up in patients (oedema) with heart failure by measuring changes in foot and lower leg volume through capture of 3D images. The trial will assess whether this device, when added to standard NHS care, improves quality of life and reduces heart failure-related events compared to standard care alone.

Inclusion: General Criteria (all participants must meet); Aged ≥18 years, AND; Diagnosis of heart failure (any aetiology or LVEF classification), AND; Documented or patient-reported moderate to severe leg oedema, AND; Lives in the UK with a home environment suitable for installation of the Heartfelt device; Pathway A: High risk patient with daily diuretics; Currently prescribed ≥40 mg/day of furosemide (or equivalent loop diuretic, eg. bumetanide or torsemide) for at least one month, AND; Any cardiorespiratory admission** in the last 12 months (Includes outpatient IV diuretics, subcutaneous loop diuretics, or escalation to combination therapy with a loop diuretic and a thiazide or thiazide-like diuretic (eg: metolazone, bendroflumethiazide, indapamide etc); Pathway B: High risk patient without daily diuretics; Patients prescribed SGLT2 inhibitor (eg; dapagliflozin or empagliflozin) , AND; Patients prescribed oral furosemide ≥40mg/day but advised to take it only as needed AND either:; at least two admissions* caused or complicated by worsening heart failure in the previous 12 months, OR b) a measurement of plasma NT-proBNP exceeding 1,000 ng/L (pg/mL) in the previous 12 months Pathway C: Implanted Haemodynamic Monitoring Devices (minimum n=10 participants); Uses an implantable device designed to monitor congestion (e.g. CardioMEMS, HeartLogic, or equivalent); Enrichment criteria: Patients must also meet a minimum total score of 4 from the characteristics below; NYHA class III and IV (score: 2); ≥80 mg/day Furosemide or equivalent loop diuretic (score: 2); <3 Number of times the patient has weighed themselves in the last 2 weeks (score: 2); Help for essential daily activities required (score: 2); GRMT score <5 (score: 2); Use of a walking stick, walker or mobility scooter (score: 2); >2 Number of HF events in last 12 months (score: 2); Aged over 75 (score: 1); Health issues limiting daily activities (score: 1); Help getting to medical appointment required (score: 1); Problematic / not tolerated uptitration of medications:; MRA (score: 1) SGLT2i (score: 1) Other (score: 1); English as a second language (score: 1); eGFR 20-45 (score: 1); Patient unable to regularly attend appointments for any reason (score: 1); >3 Number of co-morbidities (score: 1).

Exclusion: Inability to provide informed consent due to cognitive impairment; Patients with severe aortic stenosis or awaiting a heart procedure or surgery; Patient with end stage renal disease (eGFR <20); Amputation of both feet; Bed-bound for more than 20h per 24h period; Bandages to lower limbs every day; Regular wheelchair user inside their home; No fixed abode; Participation in another interventional trial that may interfere with endpoints; Life expectancy <6 months, in the opinion of the investigator; Language barriers that preclude understanding of trial procedures (unless translation resources are available in relevant language); Inability to install the device (even with assistance) allowing at least 6 months of data capture by the end of the study; Pregnancy or lack of contraceptive measures if of child-bearing potential.

ClinicalTrials.gov NCT07067658